| 1404 |
National Cancer Institute |
Html |
en |
Sleep Disorders (PDQ®)–Patient Version |
Expert-reviewed information summary about causes and management of sleep disorders in people with cancer. |
| normal sleep patterns | 0.734479 |
| Relaxation therapy | 0.493159 |
| moderate sleep disorders | 0.656166 |
| sleeping problems | 0.484122 |
| PDQ cancer information | 0.646663 |
| sleep medicines | 0.601935 |
| health care team | 0.479673 |
| clinical trials | 0.518721 |
| sleep history | 0.612308 |
| sleep apnea | 0.593611 |
| cancer patient sleeps | 0.499804 |
| cancer information summary | 0.579061 |
| clinical trial | 0.483994 |
| breast cancer prevention | 0.483786 |
| good sleep habits | 0.703452 |
| cancer patients | 0.541537 |
| treatment instructions | 0.483188 |
| sleep problems | 0.627478 |
| mild sleep disorders | 0.656367 |
| NCI’s PDQ | 0.480637 |
| NCI PDQ cancer | 0.525102 |
| Common cancer treatments | 0.495476 |
| sleep disorder clinic | 0.627008 |
| deep sleep | 0.635758 |
|
| treatment | 0.54776 |
| cancer prevention | 0.48441 |
| lighter sleep | 0.598128 |
| Cancer Information Service | 0.493437 |
| REM sleep | 0.662129 |
| sleep | 0.949433 |
| good night | 0.507447 |
| National Cancer Institute | 0.585654 |
| sleep repeat | 0.634943 |
| light sleep | 0.635787 |
| Palliative Care Editorial | 0.524141 |
| new treatment | 0.481731 |
| sleep disorders | 0.849206 |
| sleep restriction | 0.605553 |
| Cancer Care page | 0.486706 |
| Care Editorial Board | 0.525467 |
| health | 0.498616 |
| PDQ summary | 0.533115 |
| sleep disorder | 0.712776 |
| sleep problem | 0.601447 |
| cancer information summaries | 0.498019 |
| comprehensive cancer information | 0.497854 |
| cancer | 0.67715 |
| stimulus control | 0.540953 |
|
CLICK HERE |
| 1420 |
National Cancer Institute |
Html |
en |
Prostate Cancer Prevention (PDQ®)–Health Professional Version |
Expert-reviewed information summary about factors that may influence the risk of developing prostate cancer and about research aimed at the prevention of this disease. |
| hereditary prostate cancer | 0.542395 |
| prostate biopsy | 0.533126 |
| dutasteride group vs | 0.459041 |
| skin cancer | 0.446356 |
| prostate cancer period | 0.528407 |
| cancer mortality rates | 0.459369 |
| prostate volume subgroups | 0.508967 |
| Prostate Cancer Events | 0.558338 |
| finasteride group versus | 0.448086 |
| rat ventral prostate | 0.516053 |
| high-grade tumors | 0.479135 |
| high-grade cancer | 0.454168 |
| prostate cancer-specific mortality | 0.525559 |
| occult prostate cancer | 0.561891 |
| high-grade prostate cancer | 0.548137 |
| prostate preventive effects | 0.507979 |
| relative risk reduction | 0.446967 |
| radical prostatectomy | 0.460894 |
| prostate cancer mortality | 0.534065 |
| prostate cancer chemoprevention | 0.531007 |
| dietary fat | 0.445789 |
| men | 0.4492 |
| Cancer Events trial | 0.451937 |
| negative prostate biopsy | 0.515564 |
|
| digital rectal examination | 0.454846 |
| dutasteride group | 0.460003 |
| fat intake | 0.450377 |
| Cancer Prevention Trial | 0.500983 |
| prostate digital | 0.500034 |
| prostate cancer risk | 0.564597 |
| placebo group | 0.469544 |
| incident prostate cancer | 0.532469 |
| Cancer Events study | 0.447937 |
| prostate volume | 0.517049 |
| absolute risk reduction | 0.495169 |
| low biologic risk | 0.447169 |
| finasteride group | 0.448145 |
| prostate cancer | 0.910772 |
| Gleason | 0.458954 |
| clinical prostate cancer | 0.556069 |
| pancake-appearing prostate | 0.508749 |
| Prostate Cancer Prevention | 0.595277 |
| prostate cancer. | 0.505972 |
| prostate cancer death. | 0.562581 |
| statistically significant difference | 0.470146 |
| prostate cancers | 0.559985 |
| human prostate cancer | 0.538634 |
|
CLICK HERE |
| 1618 |
National Cancer Institute |
Html |
en |
Late Effects of Treatment for Childhood Cancer (PDQ®)–Patient Version |
The treatment of cancer may cause health problems (late effects) for childhood cancer survivors months or years after successful treatment has ended. Get information about the long-term physical, psychological and social effects of treatment for childhood cancer in this expert-reviewed summary. |
| childhood cancers | 0.431043 |
| cancer treatment | 0.371211 |
| body | 0.373967 |
| childhood cancer survivors | 0.770496 |
| chemotherapy | 0.372336 |
| PDQ cancer information | 0.35879 |
| total-body irradiation | 0.354372 |
| ovarian late effects | 0.364333 |
| bile duct | 0.348106 |
| talk | 0.386582 |
| chest radiation treatment | 0.353115 |
| kidney late effects | 0.373747 |
| joint late effects | 0.365129 |
| cancer information summary | 0.349224 |
| stem cell transplant | 0.480939 |
| pancreatic late effects | 0.367016 |
| heart | 0.364096 |
| symptoms | 0.373794 |
| health problems | 0.529948 |
| tests | 0.430651 |
| primary cancer diagnosis | 0.352818 |
| radiation therapy | 0.438948 |
| following | 0.347799 |
| hormone replacement therapy | 0.348511 |
|
| late effects | 0.94258 |
| treatment | 0.571093 |
| blood vessel | 0.385075 |
| primary cancer | 0.359907 |
| signs | 0.42599 |
| related health problems | 0.511763 |
| procedures | 0.374731 |
| National Cancer Institute | 0.350345 |
| spinal cord | 0.453656 |
| disease | 0.351393 |
| breast cancer risk | 0.350432 |
| breast cancer | 0.372761 |
| brain tumor | 0.349819 |
| thyroid late effects | 0.395111 |
| brain | 0.380353 |
| doctor | 0.354325 |
| radiation treatment | 0.379126 |
| radiation | 0.476283 |
| acute lymphoblastic leukemia | 0.349699 |
| health habits | 0.363956 |
| neuroendocrine late effects | 0.359016 |
| high blood pressure | 0.347712 |
| nonmelanoma skin cancer | 0.356812 |
| lung late effects | 0.390136 |
|
CLICK HERE |
| 1649 |
National Cancer Institute |
Html |
en |
Aromatherapy and Essential Oils (PDQ®)–Patient Version |
Expert-reviewed information summary about the use of aromatherapy and essential oils to improve the quality of life of cancer patients. |
| PDQ Aromatherapy | 0.51751 |
| cancer treatment | 0.518478 |
| modern aromatherapy | 0.502296 |
| certain essential oils | 0.545828 |
| aromatherapy training | 0.496531 |
| PDQ cancer information | 0.582174 |
| Cancer Complementary | 0.49782 |
| hormone -like effects | 0.496783 |
| clinical trials | 0.646919 |
| cancer information summary | 0.54045 |
| aromatherapy massage | 0.496545 |
| alternative cancer therapies | 0.488792 |
| clinical trial | 0.515897 |
| CAM cancer research | 0.479249 |
| patients | 0.520207 |
| cancer patients | 0.499565 |
| Aromatherapy products | 0.529674 |
| bergamot essential oil | 0.494855 |
| literature discuss aromatherapy | 0.518185 |
| NCI PDQ cancer | 0.50787 |
| cancer information database | 0.486869 |
| aromatherapy | 0.710126 |
| international aromatherapy programs | 0.515466 |
| Therapies Editorial Board | 0.490712 |
|
| essential oils | 0.964677 |
| cancer information | 0.591001 |
| treatment | 0.540034 |
| Complementary Therapies Editorial | 0.514222 |
| Drug Administration | 0.547203 |
| Cancer Information Specialist | 0.481775 |
| Aromatherapy research | 0.515581 |
| tree essential oils | 0.64448 |
| Cancer Information Service | 0.537651 |
| tree essential oil | 0.496279 |
| Antibacterial essential oils | 0.531896 |
| National Cancer Institute | 0.639762 |
| alternative medicine | 0.561892 |
| standard aromatherapy certification | 0.518782 |
| term aromatherapy | 0.502247 |
| orange essential oil | 0.494346 |
| aromatherapy courses | 0.496618 |
| tea tree | 0.549957 |
| cancer clinical trials | 0.48888 |
| alternative therapies | 0.505894 |
| ginger essential oil | 0.493305 |
| cancer information summaries | 0.487611 |
| cancer | 0.667969 |
| Holistic Aromatherapy | 0.506338 |
|
CLICK HERE |
| 1661 |
National Cancer Institute |
Html |
en |
Antineoplastons (PDQ®)–Health Professional Version |
Expert-reviewed information summary about antineoplastons as a treatment for people with cancer. |
| various tumor suppressor | 0.673325 |
| high-risk pediatric patients | 0.613742 |
| cell lines | 0.732784 |
| antineoplaston A10. | 0.614589 |
| steady state concentration | 0.632482 |
| mean steady state | 0.62987 |
| stable disease | 0.629423 |
| tumor suppressor genes | 0.670419 |
| antineoplaston a10 | 0.785651 |
| multiple brain metastases | 0.666381 |
| clinical trials | 0.642258 |
| cancer cell line | 0.621623 |
| cancer information summary | 0.628466 |
| highest tumor response | 0.628298 |
| patients | 0.960903 |
| cancer patients | 0.782838 |
| average dose | 0.662612 |
| human colon cancer | 0.66679 |
| tumor progression | 0.629611 |
| colon cancer cells | 0.664834 |
| antineoplaston treatment | 0.679278 |
| complete tumor response | 0.726436 |
| metastatic brain tumor | 0.711993 |
| study | 0.663173 |
| neutrophil apoptosis | 0.623745 |
|
| Human/Clinical Studies section | 0.637915 |
| neoplastic cell lines | 0.689948 |
| human blood | 0.654645 |
| cancer cells | 0.75191 |
| animal tumor systems | 0.612469 |
| National Cancer Institute | 0.656232 |
| tumor growth | 0.643714 |
| breast cancer patients | 0.772855 |
| partial tumor response | 0.663127 |
| AS2-1 | 0.676129 |
| antineoplaston therapy | 0.747438 |
| white blood cell | 0.631532 |
| antineoplaston A. | 0.675544 |
| abnormal cells | 0.630356 |
| human tumor tissue. | 0.623365 |
| human urine | 0.617971 |
| antineoplastons | 0.86378 |
| experimental cancer therapy | 0.633011 |
| chronic lymphocytic leukemia | 0.610232 |
| tumor response | 0.767878 |
| objective tumor response | 0.612044 |
| naturally occurring biochemical | 0.637098 |
| antineoplastons A10 | 0.665762 |
| cancer | 0.805413 |
|
CLICK HERE |
| 1931 |
National Cancer Institute |
Html |
es |
Tratamiento de los tumores de ovario de bajo potencial maligno (PDQ®)–Versión para pacientes |
Resumen de información revisada por expertos acerca del tratamiento de los tumores de ovario de bajo potencial maligno. |
| potencial maligno recidivantes | 0.922565 |
| siguientes procedimientos | 0.427427 |
| tarde.ampliar ecografÃa abdominal | 0.259992 |
| estadio iv | 0.702134 |
| estadio tardÃo quizás | 0.295045 |
| siguientes aspectos | 0.213133 |
| rayos x | 0.188575 |
| estadio ic | 0.522053 |
| estadio ib | 0.526427 |
| estadio ia | 0.52265 |
| National Cancer Institute | 0.172435 |
| siguientes riesgos | 0.159887 |
| tratamiento quizás | 0.234452 |
| Instituto Nacional | 0.353292 |
| áreas anormales.ampliar examen | 0.232843 |
|
| estadio iiia | 0.49525 |
| PDQ Tratamiento | 0.250127 |
| estadio iiic | 0.497145 |
| estadio iiib | 0.498374 |
| estadio iia | 0.510853 |
| estadio iib | 0.521745 |
| estadio iic | 0.517926 |
| Physician Data Query | 0.359777 |
| potencial maligno causa | 0.737758 |
| maligno causa efectos | 0.613505 |
| siguientes enlaces | 0.168488 |
| ecografÃa transvaginal.Ampliar | 0.196606 |
| histerectomÃa abdominal | 0.202556 |
| siguientes pruebas | 0.233116 |
|
CLICK HERE |
| 2015 |
National Cancer Institute |
Html |
es |
Prevención del cáncer de pulmón (PDQ®)–Versión para pacientes |
Sumario de información revisada por expertos sobre factores que influirían en el riesgo de presentar cáncer de pulmón y sobre las investigaciones dirigidas a la prevención de esta enfermedad. |
| cigarrillo encendido | 0.533546 |
| voluntarios sanos | 0.521783 |
| secciones llamadas lóbulos | 0.564444 |
| factor protector | 0.54356 |
| rayos x | 0.525531 |
| rayos gamma | 0.526755 |
| altas cantidades | 0.523911 |
| vÃas respiratorias | 0.534485 |
| suplementos vitamina | 0.527073 |
| membrana delgada llamada | 0.563077 |
| National Cancer Institute | 0.526876 |
| Más personas | 0.538369 |
| Instituto Nacional | 0.548081 |
|
| antecedentes familiares | 0.770813 |
| siguientes factores | 0.598507 |
| Physician Data Query | 0.601335 |
| gas radón | 0.544843 |
| prevención revisa | 0.523285 |
| PDQ Prevención | 0.542908 |
| siguientes sustancias | 0.533013 |
| Menor exposición | 0.544963 |
| órganos respiratorios | 0.535883 |
| principal causa | 0.53309 |
| factores protectores | 0.947087 |
| siguientes sumarios | 0.567797 |
| suplementos alimenticios | 0.525893 |
|
CLICK HERE |
| 2037 |
National Cancer Institute |
Html |
es |
Prevención del cáncer de piel (PDQ®)–Versión para profesionales de salud |
Sumario de información revisada por expertos sobre factores que pueden influir en el riesgo de presentar cáncer de piel y sobre las investigaciones dirigidas a prevenir esta enfermedad. |
| skin cancer | 0.991265 |
| cutaneous melanoma | 0.469757 |
| Lippincott Williams | 0.41932 |
| skin cancer prevention | 0.612003 |
| prevent skin | 0.440602 |
| protectores solares | 0.469609 |
| Williams GM | 0.418343 |
| queratosis solares | 0.585992 |
| Sin embargo | 0.685934 |
| protector solar | 0.843096 |
| American Cancer Society | 0.553421 |
| Prev Med | 0.458565 |
| cancer prevention study | 0.448174 |
| case-control study | 0.424296 |
| Study Group | 0.427125 |
| DeVita VT Jr | 0.43478 |
| risk factors | 0.435855 |
| with nonmelanoma skin | 0.42056 |
| isotretinoin-basal cell carcinomas | 0.418488 |
| randomized trial | 0.462527 |
| exposición solar | 0.710997 |
| Natl Cancer Inst | 0.487884 |
| 8th ed | 0.41947 |
| protección solar | 0.624745 |
| melanoma risk factors | 0.418328 |
|
| pruebas insuficientes | 0.419855 |
| Nambour Skin Cancer | 0.466485 |
| cell carcinomas | 0.512878 |
| Halliday GM | 0.422507 |
| Arch Dermatol | 0.425176 |
| Wilson LD | 0.417928 |
| Cancer Facts | 0.43005 |
| Aasi SZ | 0.421096 |
| nevos melanocÃticos benignos | 0.418665 |
| protector solar ayuda | 0.422241 |
| controlled trial | 0.45893 |
| protector solar versus | 0.425736 |
| Epidemiol Biomarkers Prev | 0.463973 |
| exposición solar aguda | 0.467654 |
| Cancer Prevention Trial | 0.454925 |
| Thomas VD | 0.418204 |
| Reduce Actinic Cancer | 0.419285 |
| radiación uv | 0.425436 |
| randomized controlled trial | 0.440826 |
| radiación solar | 0.432514 |
| crema base | 0.420169 |
| nonmelanoma skin cancer | 0.715174 |
| radiación ultravioleta | 0.572893 |
| Cancer Study Group | 0.420229 |
|
CLICK HERE |
| 2106 |
National Cancer Institute |
Html |
es |
Exámenes de detección del cáncer de endometrio (PDQ®)–Versión para pacientes |
Sumario de información revisada por expertos sobre pruebas que se usan para detectar el cáncer de endometrio. |
| PDQ Tratamiento | 0.669269 |
| general causa sÃntomas | 0.588555 |
| Visuals Online | 0.525614 |
| PDQ Exámenes | 0.596864 |
| cáncer.Los exámenes | 0.641713 |
| Physician Data Query | 0.681868 |
| pequeña cantidad | 0.54391 |
| Estados Unidos | 0.562116 |
| cuello uterino | 0.811632 |
|
| prevención revisa | 0.531482 |
| ecografÃa endovaginal | 0.56717 |
| información ayuda | 0.538498 |
| National Cancer Institute | 0.545187 |
| ecografÃa transvaginal | 0.942856 |
| siguientes riesgos | 0.532576 |
| siguientes sumarios | 0.618993 |
| Instituto Nacional | 0.58569 |
|
CLICK HERE |
| 3653 |
National Cancer Institute |
Html |
es |
Cannabis y canabinoides (PDQ®)–Versión para pacientes |
Resumen de información revisada por expertos sobre el uso del Cannabis y canabinoides para el tratamiento de los efectos secundarios relacionados con el tratamiento del cáncer como la náusea y el vómito. |
| suficiente información | 0.303746 |
| American Academy | 0.304933 |
| salud masculina | 0.30438 |
| Controlled Substances Act | 0.309374 |
| estado.ampliar mapa | 0.305022 |
| NCI Best Case | 0.309795 |
| Ley Boggs | 0.304951 |
| ratones modelo | 0.329727 |
| Asia central | 0.304897 |
| datos bibliográficos pubmed | 0.306457 |
| principal canabinoide | 0.317402 |
| continuas preocupaciones | 0.305444 |
| Instituto Nacional | 0.356831 |
| distintos métodos | 0.304585 |
| Salud Complementaria | 0.311676 |
| Asociación Médica Americana | 0.308343 |
| complementarias revisa | 0.305401 |
| huésped aguda | 0.30517 |
| posibles efectos | 0.307656 |
| siglo xix | 0.305316 |
| Estados Unidos | 0.923075 |
| Investigational New Drug | 0.308776 |
| ¿Los beneficios | 0.303644 |
| Centro Nacional | 0.308445 |
| células madre | 0.307765 |
|
| New Hampshire Avenue | 0.305866 |
| creciente interés | 0.305364 |
| Drug Administration | 0.303686 |
| vÃa oral | 0.438627 |
| medicamentos canabinoides | 0.315665 |
| lista i | 0.304143 |
| Marijuana Tax Act | 0.30965 |
| Men's Health Study | 0.308077 |
| siguientes riesgos | 0.303989 |
| suficientes pruebas | 0.305693 |
| Visuals Online | 0.304212 |
| sistema nervioso central | 0.330645 |
| Physician Data Query | 0.323581 |
| libre uso | 0.304331 |
| principal ingrediente | 0.304814 |
| receptores canabinoides | 0.313898 |
| posibles beneficios | 0.304408 |
| página manejo | 0.303972 |
| ¿El tratamiento | 0.309063 |
| planta cannabis | 0.341326 |
| potencial alto | 0.304956 |
| medicina complementaria | 0.465284 |
| largo tiempo | 0.303689 |
| ¿el cannabis | 0.355862 |
|
CLICK HERE |